Occasional Publications on Northern Life, No. 04

The need to exchange information on research in reindeer and caribou diseases became apparent to investigators attending the Second International Reindeer/Caribou Symposium in Roros, Norway, in 1979. Initially, bibliographies were to be exchanged by being submitted to and subsequently distributed by workers at the University of Alaska. When the bibliographies were submitted, it seemed sensible to computerize the lists to facilitate searches for specific information in the future. An apparently simple task became amazingly complex. This is the resultant collection of publications by reindeer/caribou disease researchers. Because researchers in wildlife diseases tend to work on more than one species or topic, out of interest or necessity, a decision was made to include all of a person's references rather than to limit them to strictly reindeer/caribou diseases. The authors hope this will provide a good basis for exchange of information among all those interested in reindeer/caribou diseases

Circular 72

Orphan reindeer fawns are often observed at summer handlings. Sometimes an abandoned fawn is found on the range. These fawns can be saved and raised for pets or for sale as live animals. There is an increasing demand for live reindeer to be shipped to locations outside Alaska. Tame reindeer adapted to a commercial diet can be a potential source of income for the herder as well as a rewarding project for the family. The following information is intended for reindeer herders in Alaska who do not have ready access to modem veterinary facilities or care

Effects of live Brucella abortus strain 19 vaccine on reindeer later challenge exposed with Brucella suis type 4

Twelve reindeer (Rangifer tarandus) were vaccinated with Brucella abortus strain 19 vaccine and challenge exposed with B. suis type 4 two and one-half months later during mid-gestation. An additional 10 reindeer served as non-vaccinated controls. A sharp serologic titer response was observed in both vaccinates and controls. Brucella suis type 4 was isolated from tissues and blood from most controls (8 of 10, and 7 of 10 respectively). Seven of 11 vaccinated cows aborted, gave birth to weak fawns that died, or were not pregnant at the completion of the experiment. Brucella suis type 4 was isolated from the tissue of 4 of 12 vaccinates at necropsy. It was concluded that, under the conditions of this experiment, B. abortus strain 19 vaccine in reindeer did not provide adequate protection against challenge exposure with virulent B. suis type 4 organisms

Effects of live Brucella abortus strain 19 vaccine on reindeer

Twenty female and seven male reindeer (Rangifer tarandus) were vaccinated subcutaneously in the right shoulder with a 1-ml dose of approximately 1.2 x 108 colony forming units of Brucella abortus strain 19, the standard reduced dose for cattle. An additional three females and one male served as non-vaccinated sentinels. Brucella abortus strain 19 was isolated from two of three fetuses aborted by vaccinated females during the first of two fawning seasons. Serologic titers to brucellosis in the vaccinates peaked by 46 days post-vaccination. Shedding of B. abortus strain 19 by vaccinated animals was indicated by seroconversion of all four sentinels. Titers in the sentinels were low and sporadic. Brucella abortus strain 19 was isolated from the tissues and fetus of a pregnant female 51 days post-vaccination and from the carpal joint of another female 7 months post-vaccination. Based on these results and a previous challenge experiment, it was concluded that Brucella abortus strain 19 is not a suitable vaccine to use in a brucellosis control program in reindeer

HLA variation and disease

Fifty years since the first description of an association between HLA and human disease, HLA molecules have proven to be central to physiology, protective immunity and deleterious, disease-causing autoimmune reactivity. Technological advances have enabled pivotal progress in the determination of the molecular mechanisms that underpin the association between HLA genetics and functional outcome. Here, we review our current understanding of HLA molecules as the fundamental platform for immune surveillance and responsiveness in health and disease. We evaluate the scope for personalized antigen-specific disease prevention, whereby harnessing HLA–ligand interactions for clinical benefit is becoming a realistic prospect